8-K: Scholar Rock Announces Positive Preclinical Data for SRK-439 and Doses First Participants in Phase 2 Obesity Trial

Scholar Rock presented new preclinical data showing SRK-439, a myostatin inhibitor, preserves lean mass and attenuates fat rebound after GLP-1 receptor agonist withdrawal, and has dosed the first participants in a Phase 2 trial for apitegromab in obesity.

Summary

• Scholar Rock announced new preclinical data for SRK-439, a myostatin inhibitor, showing it helps maintain lean muscle mass and reduces fat regain after stopping GLP-1 receptor agonist (GLP-1 RA) treatment.
• The preclinical study used a mouse model of diet-induced obesity, where mice received either semaglutide with a control antibody or semaglutide with SRK-439.
• After four weeks of treatment, semaglutide was stopped, and the mice continued with either the control antibody or SRK-439 for another four weeks.
• Mice treated with SRK-439 showed significantly higher lean mass (65.8%) and lower fat mass (18.0%) at the end of the withdrawal period compared to the control group (57.1% lean mass and 28.7% fat mass).
• The company also announced the first participants were dosed in the Phase 2 EMBRAZE trial, which will evaluate apitegromab, another myostatin inhibitor, in obese individuals on GLP-1 RA therapy.
• The EMBRAZE trial aims to assess the safety and efficacy of apitegromab in preserving lean muscle mass and the durability of weight loss after GLP-1 RA withdrawal.

Sentiment

Score: 8

Explanation: The document presents positive preclinical data and the initiation of a Phase 2 trial, indicating strong progress and potential for future success. The focus on lean mass preservation is a key differentiator in the obesity treatment space.

Positives

• SRK-439 demonstrated a significant increase in lean mass and reduced fat mass rebound in preclinical studies.
• The EMBRAZE trial has commenced ahead of schedule, indicating efficient progress in the clinical program.
• SRK-439 shows potential for healthier weight management by preserving lean mass during weight loss.
• Apitegromab is being investigated for its ability to maintain lean muscle mass in obese individuals on GLP-1 RA therapy.

Risks

• Preclinical results may not translate directly to human clinical trials.
• The efficacy and safety of SRK-439 and apitegromab have not been established in humans.
• Clinical trials may not yield the desired results or may encounter unforeseen challenges.
• Regulatory approvals are not guaranteed and may be subject to delays.

Future Outlook

Scholar Rock is looking forward to providing additional updates on its cardiometabolic program as they advance SRK-439 and the EMBRAZE trial.

Management Comments

• Jay Backstrom, M.D., MPH, President and Chief Executive Officer at Scholar Rock, stated they are happy to share the exciting news that they've dosed the first participants in their EMBRAZE clinical trial ahead of schedule.
• Jay Backstrom also noted the new preclinical data with SRK-439, their highly selective anti-myostatin, featured at the American Diabetes Association Scientific Sessions.
• Mo Qatanani, PhD, Chief Scientific Officer at Scholar Rock, stated that the new preclinical data provides compelling evidence that SRK-439 contributed to lean muscle preservation during GLP-1 RA-induced weight loss and attenuated fat mass rebound following discontinuation of semaglutide.

Industry Context

The announcement is relevant to the growing interest in treatments for obesity and the challenges of maintaining weight loss after GLP-1 RA therapy. The focus on preserving lean mass is a key differentiator in this space.

Comparison to Industry Standards

• The study compares SRK-439 to a control group receiving semaglutide and an IgG antibody, which is a standard approach in preclinical studies.
• The results show SRK-439's potential to improve upon the limitations of GLP-1 RAs, which often lead to lean mass loss and weight regain.
• The company notes that SRK-439 has greater potency compared to an anti-ACTRII antibody, suggesting a potential competitive advantage.
• The EMBRAZE trial is designed to evaluate apitegromab in combination with GLP-1 RAs, which is a common approach in the industry to enhance weight loss and metabolic benefits.

Stakeholder Impact

• Shareholders may view the positive preclinical data and clinical trial initiation favorably.
• Patients with obesity may benefit from the development of new treatments that preserve lean mass.
• The company's employees are involved in the research and development of these treatments.
• The company's suppliers and partners may be impacted by the progress of these programs.

Next Steps

• Scholar Rock will continue to advance the development of SRK-439.
• The company will provide updates on the progress of the EMBRAZE trial.
• Further data from the EMBRAZE trial will inform the development of SRK-439.

Key Dates

Keywords

SRK-439, apitegromab, myostatin inhibitor, GLP-1 receptor agonist, obesity, lean mass, fat mass, weight management, clinical trial, preclinical study